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palliative therapy, simple WBRT or simple chemotherapy, combined 
radiochemotherapy, stereotactic linac-based radiosurgery plus che-
motherapy/ WBRT and neurosurgical resection plus chemotherapy/ 
WBRT. Ninety-two specimens of lung cancer were examined for P53, 
nm23 and VEGF by immunohistochemical staining. Survival analysis 
was compared with Kaplan-Meier method and log-rank test was used 
respectively. Statistical signiﬁcance was deﬁned as P<0.05. 
Results: The univariate analysis showed that performance status, age, 
the number of brain metastases, the absence or presence of extracranial 
metastases and metastatic symptoms had inﬂuences over survival pe-
riod. The multivariate analysis showed that performance status, age and 
the absence or presence of extracranial metastases were related to prog-
nosis. The median survival time of patients receiving palliative therapy, 
simple WBRT or simple chemotherapy, combined radiochemotherapy, 
stereotactic linac-based radiosurgery plus chemotherapy/ WBRT and 
neurosurgical resection plus chemotherapy/ WBRT was 1.7 months, 
3.2 months, 9.0 months, 10.6 months and 17.1 months respectively. 
The median survival time of patients with P53(+)/P53(-), nm23(+)/(-) 
and VEGF(+)/(-)was 11.7/10.6months (P=0.5179), 12.8/9.9 months 
(P=0.1075) and 10.6 /12.0 months (P=0.0231) respectively. 
Conclusions: Performance status, age and the absence or presence of 
extracranial metastases are the independent prognostic factors. The 
patients with PS score 0~1, age< 60 years and the absence of extracra-
nial metastases have longer survival time and they would beneﬁt from 
aggressive treatment modalities. Either combined radiochemotherapy 
or stereotactic linac-based radiosurgery plus chemotherapy/ WBRT 
is effective. There is a longer survival tendency in patients receiving 
stereotactic linac-based radiosurgery plus chemotherapy/ WBRT. The 
expression of VEGF is related to the survival of the patients while 
the expression of P53 and nm23 is unrelated to the survival time. The 
patients with VEGF positive expression have shorter survival time.
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Purpose: The purpose of this study was to evaluate the feasibility of 
sleeve lobectomy after induction chemoradiotherapy.
Methods: We reviewed seven patients who underwent sleeve lobec-
tomy after inductin chemoradiotherapy(Group A) for locally advanced 
non-small cell lung cancer, and 19 patients who underwent sleeve 
lobectomy without induction therapy(Group B). 
Results: The complication of group A was in 3 (33%) of 7 cases, 1 
necrosis of apex of lower lobe, 1 atelectasis and 1 arrhythmia. Of 
group B was in 9(47%) of 19 cases, 2 failure of anastomosis, 3 air 
leakage>7day, 3 wound infection, 2 arrhythmia, 2 recurrent nerve palsy, 
and 1 pneumonia. The recurrence of group A was in 2(29%) of 7 cases. 
One case was brain on the 220th and pulmonary on the 430th. Another 
one case was kidney on the 365th and duodenum on the 700th. The 
recurrence of group B was in 3(16%) of 19 cases, which were observed 
in 1 pulmonary, 1 skin, and 1 plural, respectively.
Conclusions: The complication of bronchial anastomosis and local 
recurrence was not permitted in group A. Although it is a small number 
of study, sleeve lobectomy with induction chemoradiotherapy is con-
sidered to be feasible technique from safety and oncologically.
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Background: Conventional treatment for non-small cell lung cancer 
(NSCLC) brain metastases (BM) is whole-brain radiotherapy (WBRT). 
The efﬁcacy is limited. It might be increased by a potent radiosen-
sitiser such as gemcitabine, which is believed to cross the disrupted 
blood–brain barrier. Primary objective of this study was to determine 
the maximum tolerated dose (MTD) of weekly gemcitabine given 
concurrently with WBRT. 
Methods: Patients with BM from NSCLC were included. The dose of 
WBRT was 3750 cGy (total 15 times, 3 weeks). Gemcitabine was given 
concurrent with WBRT on days 1 and 8 and 15. Starting dose was 400 
mg/m2, escalated by 100 mg/m2 increments. At least three patients were 
included per level. Dose limiting toxicity (DLT) was deﬁned as grade 
4 hematological or grade 2 neurological toxicity. When two or more 
patients experience DLT, the MTD was reached. 
Results: A total of 16 patients were included; 69% had a PS 1. A total 
of 69% had concurrent active extra cranial diseases. All had more than 
3 BM. Up to 600 mg/m2 (level 3) no neurology toxicity was observed. 
At 600 mg/m2, two out of 6 patients developed grade 4 thrombocyto-
penia. One of the two patients’ thrombocytopenia was confused with 
disseminated intravascular coagulation (DIC). At 700 mg/m2, two out 
of 4 patients developed neurotoxicities. One developed grade 3 seizure 
and confusion. Another patient developed suspected grade 2 muscle 
weakness(neuropathy motor). 
Conclusions: The MTD was reached at dose 700 mg/m2. The dose of 
600 mg/m2 would be considered for further study. 
This study was supported by the China Society Clinical of Oncology 
foundation (No.Y-2005--0010) 
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